FO
PCRX icon

FT Options’s Pacira BioSciences PCRX Stock Holding History

FT Options’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-5,000
Closed -$72K – 260
2017
Q1 		$72K Buy
+5,000
New +$216K 0.09% 131
2016
Q1 		– Sell
-2,000
Closed -$2K – 335
2015
Q4 		$2K Buy
+2,000
New +$113K ﹤0.01% 196

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

FT Options's PCRX Position: Q2 2017 in Review

FT Options sold out of Pacira BioSciences (PCRX) in Q2 2017, closing a stake of 5,000 shares — an estimated $228K sold.

FT Options first reported a position in PCRX in Q4 2015 and held it in 2 quarters. The position peaked at $269K in Q4 2015. 196 funds tracked by Wall St. Rank hold PCRX as of Q2 2017.

  • FT Options reported no remaining Pacira BioSciences position as of Q2 2017 after selling out during the quarter.
  • FT Options sold 5,000 Pacira BioSciences shares in Q2 2017, an estimated $228K.
  • FT Options first reported a position in Pacira BioSciences in Q4 2015 and held it in 2 quarters.
  • FT Options's Pacira BioSciences position peaked at $269K in Q4 2015.
  • 196 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2017.

Based on FT Options's 13F filing for Q2 2017, filed 11 Aug 2017.